PL433329A1 - Conjugate of a fusion protein containing an IgG1 Fc fragment with a sequence fragment of the human fibroblastic growth factor FGF2 and its use - Google Patents

Conjugate of a fusion protein containing an IgG1 Fc fragment with a sequence fragment of the human fibroblastic growth factor FGF2 and its use

Info

Publication number
PL433329A1
PL433329A1 PL433329A PL43332920A PL433329A1 PL 433329 A1 PL433329 A1 PL 433329A1 PL 433329 A PL433329 A PL 433329A PL 43332920 A PL43332920 A PL 43332920A PL 433329 A1 PL433329 A1 PL 433329A1
Authority
PL
Poland
Prior art keywords
fragment
fusion protein
growth factor
protein containing
igg1
Prior art date
Application number
PL433329A
Other languages
Polish (pl)
Other versions
PL242970B1 (en
Inventor
Anna SZLACHCIC
Karolina Jendryczko
Natalia Skinder
Julia Chudzian
Daniel KROWARSCH
Jacek OTLEWSKI
Original Assignee
Uniwersytet Wrocławski
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Uniwersytet Wrocławski filed Critical Uniwersytet Wrocławski
Priority to PL433329A priority Critical patent/PL242970B1/en
Publication of PL433329A1 publication Critical patent/PL433329A1/en
Publication of PL242970B1 publication Critical patent/PL242970B1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/50—Fibroblast growth factor [FGF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Przedmiotem wynalazku jest białko fuzyjne zawierające C-końcowy fragment Fc pochodzący z immunoglobuliny G1 oraz fragment sekwencji (48-68) ludzkiego fibroblastycznego czynnika wzrostu FGF2 (sekwencja DPHIKLQLQAEERGVVSIKGV), połączone z silnym związkiem cytotoksycznym, sposób otrzymywania koniugatu cytotoksycznego opartego o opisane białko fuzyjne i jego zastosowanie jako lek.The subject of the invention is a fusion protein containing a C-terminal Fc fragment derived from immunoglobulin G1 and a sequence fragment (48-68) of the human fibroblastic growth factor FGF2 (DPHIKLQLQAEERGVVSIKGV sequence), combined with a strong cytotoxic compound, a method for the preparation of a cytotoxic conjugate based on the described fusion protein and its use as a medicine.

PL433329A 2020-03-24 2020-03-24 Fusion protein, a conjugate comprising said fusion protein, and uses thereof PL242970B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PL433329A PL242970B1 (en) 2020-03-24 2020-03-24 Fusion protein, a conjugate comprising said fusion protein, and uses thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PL433329A PL242970B1 (en) 2020-03-24 2020-03-24 Fusion protein, a conjugate comprising said fusion protein, and uses thereof

Publications (2)

Publication Number Publication Date
PL433329A1 true PL433329A1 (en) 2021-09-27
PL242970B1 PL242970B1 (en) 2023-05-29

Family

ID=78055819

Family Applications (1)

Application Number Title Priority Date Filing Date
PL433329A PL242970B1 (en) 2020-03-24 2020-03-24 Fusion protein, a conjugate comprising said fusion protein, and uses thereof

Country Status (1)

Country Link
PL (1) PL242970B1 (en)

Also Published As

Publication number Publication date
PL242970B1 (en) 2023-05-29

Similar Documents

Publication Publication Date Title
CN112512581B (en) Antibody constructs against CLDN18.2 and CD3
US20220340676A1 (en) Modified human igm constant regions for modulation of complement-dependent cytolysis effector function
MX2023005420A (en) Humanized bcma antibody and bcma-car-t cells.
EA201991577A1 (en) NEW ANTIBODIES AGAINST THE HUMAN TRANSFERRIN RECEPTOR, ABLE TO BREAK THE HEMATOENCEPHALIC BARRIER
RU2019121902A (en) REGULATORY T-CELL POLYVALENT MODULATORS
JP2020519643A5 (en)
KR20220034920A (en) Novel monoclonal antibodies to cytotoxic t-lymphocyte-associated protein 4 (ctla-4)
WO2019148026A8 (en) Il-22 fc fusion proteins and methods of use
NZ717847A (en) Human antigen binding proteins that bind beta-klotho, fgf receptors and complexes thereof
EP4342541A3 (en) Antibody fc variants for increased blood half-life
TW202317623A (en) Il2-based therapeutics and methods of use thereof
PT2173381E (en) Fc receptor-binding polypeptides with modified effector functions
PE20211293A1 (en) MONOCLONAL ANTIBODIES ANTAGONISTS AGAINST CD40 AND THEIR USES
EP4292649A3 (en) Fusion protein comprising nerve growth factor and preparation method and use thereof
ZA202300862B (en) Flt3 ligand fusion proteins and methods of use
PL415888A1 (en) Method for producing insulin and its derivatives and the hybrid peptide used in this method
PE20221865A1 (en) ANTIBODIES AGAINST YELLOW FEVER VIRUS AND METHODS OF THEIR GENERATION AND USE
PE20220217A1 (en) HUMANIZED ANTIBODIES AGAINST THE BETA CHAIN REGION OF THE 9TH FAMILY TRBV9 OF THE HUMAN TCR, AND THEIR METHODS OF USE
CN102341496A (en) Humanized pcrv antibody having anti-pseudomonal activity
SG11201901317TA (en) Anti-pd-l1 antibody
AR114436A1 (en) CANNABINOID TYPE 1 (CB1) RECEPTOR BINDING PROTEINS AND USES OF THEM
EA201690056A1 (en) ARTIFICIAL PROTEINS CONNECTING THE FACTOR N (fHbp), AND METHODS OF THEIR APPLICATION
PL433329A1 (en) Conjugate of a fusion protein containing an IgG1 Fc fragment with a sequence fragment of the human fibroblastic growth factor FGF2 and its use
WO2023046085A8 (en) Tpo mimetic fusion proteins and methods of use
RU2021128024A (en) METHODS FOR CULTIVATION OF CELLS